Plate IV - doses as study parameters, not protocols
Thymulin dosage in studies, reported as it appears in the literature.
The doses, routes, and pharmacokinetics on record - all of them study parameters in animals and cells, none of them a human protocol.
The short version, in plain words
There is no established thymulin dosage for people - so this page reports only what researchers gave to animals and cells. In rodent studies the amounts were tiny: nanograms to a few micrograms per animal, given by injection into the belly cavity or the brain fluid, or as roughly 100 nanograms per kilogram a day under the skin in one rat study. The gene-therapy work doesn't dose the peptide at all - it delivers a single shot of the gene instead. None of these numbers is a recommendation, a regimen, or a protocol a person should follow. They are study settings, written down so the record is complete.
Thymulin Peptide Dosage in Animal and In-Vitro Studies
Thymulin peptide dosage in the published record lives entirely in animal and in-vitro work. Reported research doses include 0.1-1 microg intracerebroventricularly (into the brain's fluid spaces) and 1-1000 ng intraperitoneally (into the abdominal cavity) in rodent pain models, and roughly 100 ng/kg/day subcutaneously in a rat pulmonary-hypertension study [4]. In one mouse tissue-protection study, serum thymic factor was given at 50 microg per animal before an LPS challenge [15]. Anti-inflammatory mouse work dosed thymulin daily for two weeks before the challenge, with the numeric amount reported in the source rather than the abstract [6].
These are study parameters tied to a species, a route, and an endpoint - not a scale that converts to a human dose. The atlas reports them so the literature is legible, never as guidance.
What is the dosage of thymulin peptide?
There is no established human dose. Studies report research doses in animals - for example 0.1-1 microg intracerebroventricularly, 1-1000 ng intraperitoneally, or about 100 ng/kg/day subcutaneously - and these are study parameters, not protocols for people [4]. Gene-therapy work used a single vector dose rather than a peptide dose [5]. No human thymulin dosing regimen is established in the literature.
What doses of thymulin were used in animal studies?
Reported research doses include 0.1-1 microg intracerebroventricularly and 1-1000 ng intraperitoneally in rodent pain models, and roughly 100 ng/kg/day subcutaneously in a rat pulmonary-hypertension study [4]; a separate mouse study used 50 microg per animal of serum thymic factor before LPS [15]. Gene-therapy work used a single adenoviral or nanoparticle vector dose rather than a peptide dose [5][7].
How is thymulin administered in research?
In animal and in-vitro studies, thymulin has been given by intraperitoneal, subcutaneous, and intracerebroventricular routes, with intratracheal and intramuscular delivery used for gene-therapy vectors and a topical zinc-thymulin formulation used in a small human cosmetic pilot [5][7]. The route follows the question: systemic for inflammation, central for CNS and pain work, airway for the inhaled gene therapy [6][7].
Is thymulin taken as an injection?
In research, thymulin has been delivered by injection routes - intraperitoneal, subcutaneous, and intracerebroventricular - in animals, and a human topical zinc-thymulin pilot used a skin formulation [7]. There is no approved human injectable thymulin product. Any injection described in the literature is an experimental route in a study animal, not a human regimen.
What is the half-life of thymulin?
As a small peptide, native thymulin has a short circulating half-life, but a precise human pharmacokinetic half-life is not well established in the public literature [5]. That short native persistence is one reason gene-therapy approaches were developed - to sustain circulating thymulin from an internal source rather than chase it with repeated dosing [5][7]. The honest statement is that the thymulin half-life in humans is uncharacterized.
What is known about thymulin safety and side effects?
Honestly, little in humans. Thymulin is a research peptide, not an FDA-approved drug and not a dietary supplement, and the human safety record is sparse and dated - several human studies used a synthetic analog (nonathymulin) rather than native thymulin [5]. The preclinical work reports therapeutic and protective effects in animal models rather than systematic toxicology [6][7]. Because activity is strictly zinc-dependent, reported effects are also entangled with zinc status, which complicates any clean safety read. There is no established human side-effect profile, and nothing here is dosing guidance.